Alexion Pharma (ALXN) Tops Q3 EPS by 28c, Revenues Beat; Boosts FY18 EPS/Revenue/Operating Margin Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Reports Third Quarter 2018 Results
October 24, 2018 6:35 AM EDT3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase 3Q18 GAAP diluted EPS of $1.47 per share; non-GAAP diluted EPS of $2.02 per share Updated 2018 full-year guidance given the strength of the business Positive topline Phase 3 data for eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD); regulatory submissions planned for early 2019 Announced agreement to acquire Syntimmune and collaboration with Dicerna
BOSTON--(BUSINESS WIRE)--... More
